# Re-evaluation Task: HN3-028

## Context
- **Case ID**: HN3-028
- **Cancer type**: Scalp Cutaneous Melanoma, BRAF V600E-Positive
- **Stage**: Stage IIIC (T4bN2cM0), ulcerated, with in-transit metastases
- **Molecular profile**: BRAF V600E mutation, T4b ulcerated primary, In-transit metastases (N2c), Scalp location
- **Report file**: experiment_reports\HN3-028_report.json
- **Current score**: 84/100
- **Gap analysis (local GPU)**: The most critical gaps in the HN3-028 cancer research report are the lack of data on Adjuvant Dabrafenib plus Trametinib (12 Months) for metastatic/unresectable cases and Wide Local Excision with Sentinel Lymph Node Biopsy, as these are essential components of comprehensive treatment protocols that require more detailed information to accurately assess their efficacy. Filling in these gaps will improve the score by providing a more complete picture of the effectiveness of various treatments for different stages and types of cancer, allowing for more informed decision-making and potentially leading to better patient outcomes.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  12/25  |  48.0% |
| tier_coverage                       |   8/10  |  80.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| structural_integrity                |  15/15  | 100.0% |
| rating_calibration                  |  15/15  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (48.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\HN3-028_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Scalp Cutaneous Melanoma, BRAF V600E-Positive",
    "stage": "Stage IIIC (T4bN2cM0), ulcerated, with in-transit metastases",
    "molecular_profile": [
      "BRAF V600E mutation",
      "T4b ulcerated primary",
      "In-transit metastases (N2c)",
      "Scalp location"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Neoadjuvant Nivolumab plus Ipilimumab Followed by Surgery",
      "category": "Immunotherapy (Neoadjuvant)",
      "composite_rating": 8.3,
      "rating_breakdown": {
        "evidence_level": {
          "score": 9,
          "rationale": "Phase 3 NADINA trial: 12-month EFS 83.7% vs 57.2% with adjuvant nivolumab alone; 68% reduction in recurrence/death; 2-year EFS 77.3% vs 55.7%; practice-changing results now standard of care for resectable stage III"
        },
        "survival_benefit": {
          "score": 9,
          "rationale": "2-year EFS 77.3% with neoadjuvant vs 55.7% adjuvant; 2-year DMFS 82.8% vs 63.9%; 59% major pathological response rate; patients with MPR had 95.1% 12-month RFS; transformative outcome improvement"
        },
        "accessibility": {
          "score": 8,
          "rationale": "Both nivolumab and ipilimumab FDA approved; neoadjuvant approach now endorsed by NCCN 2025 guidelines; requires only 2 cycles pre-surgery"
        },
        "safety_profile": {
          "score": 6,
          "rationale": "Immune-related adverse events with combined checkpoint inhibition; grade 3/4 AEs in ~30%; hepatitis, colitis, endocrinopathies; short duration (2 cycles) limits cumulative toxicity"
        },
        "biomarker_match": {
          "score": 8,
          "rationale": "Effective regardless of BRAF status in NADINA; IFN-gamma signature, TMB, and PD-L1 predictive; scalp melanoma's higher TMB may enhance response; ulcerated melanomas may respond better to immunotherapy"
        }
      },
      "mechanism_of_action": "Combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) checkpoint blockade activates both effector and regulatory T-cell compartments, generating robust anti-tumor immunity. Neoadjuvant administration in the presence of intact tumor provides maximal antigen exposure for immune priming, generating superior systemic anti-tumor immunity compared to adjuvant therapy post-resection.",
      "key_evidence": {
        "study_name": "NADINA Trial",
        "journal": "New England Journal of Medicine",
        "year": 2024,
        "sample_size": 423,
        "os_months": {
          "treatment": 0,
          "control": 0,
          "hazard_ratio": 0.32,
          "p_value": 0.0001
        },
        "pfs_months": {
          "treatment": 0,
          "control": 0
        },
        "orr_percent": {
          "treatment": 59,
          "control": 0
        }
      },
      "biomarker_requirements": [
        "Resectable stage III melanoma"
      ],
      "notable_side_effects": [
        "Immune-related hepati
... (truncated — read full file from experiment_reports\HN3-028_report.json)
```
